PWMG
SGMO

Prestige Wealth Management Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Prestige Wealth Management Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75 Hold
300
– – ﹤0.01% 1113
2025
Q4 		$126 Buy
+300
New +$159 ﹤0.01% 996

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Prestige Wealth Management Group's SGMO Position: Q1 2026 in Review

Prestige Wealth Management Group held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 300 shares worth $75. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

Prestige Wealth Management Group first reported a position in SGMO in Q4 2025 and has held it in 2 quarters since. The position peaked at $126 in Q4 2025. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Prestige Wealth Management Group held 300 shares of SANGAMO THERAPEUTICS INC worth $75 as of Q1 2026.
  • Prestige Wealth Management Group left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Prestige Wealth Management Group's portfolio in Q1 2026, its #1113 holding.
  • Prestige Wealth Management Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2025 and has held it in 2 quarters since.
  • Prestige Wealth Management Group's SANGAMO THERAPEUTICS INC position peaked at $126 in Q4 2025.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Prestige Wealth Management Group's 13F filing for Q1 2026, filed 13 May 2026.